Monday, May 31, 2021

Paper in Nature Genetics: Genome-wide Meta-Analysis Shows That Research into Different Ancestries Leads to Better Results and Better Care

Investigator(s): Jerome I Rotter, MD

LOS ANGELES — Today The Lundquist Institute announced that its investigators contributed data from several studies, including data on Hispanics, African-Americans and East Asians, to the international MAGIC collaboration, composed of more than 400 global academics, who conducted a genome-wide association meta-analysis led by the University of Exeter. Now published in Nature Genetics, their findings demonstrate that expanding research into different ancestries yields more and better results, as well as ultimately benefitting global patient care.

Monday, May 24, 2021

Yan Group’s Research Shows That Motile Cilia Are Key to Oocyte Pickup in the Fallopian Tube

Investigator(s): Wei Yan, MD, PhD
Unlike the normal Fallopian tube (left), the "cilia-less" Fallopian tube fails to pick up ovulated eggs, leading to female infertility (right). Art by Tingting Xie.

LOS ANGELES — Today, The Lundquist Institute announced that Wei Yan, MD, PhD, and his research group have solved a longstanding mystery and scientific debate about the mechanism underlying the gamete and embryo transport within the Fallopian tube. Using a mouse model where the animals lacked motile cilia in the oviduct, Dr.

Thursday, May 13, 2021

Dr. Ibrahim’s start-up Vitalex Biosciences is manufacturing humanized monoclonal antibodies that would stem the spread of this fatal disease

Investigator(s): Ashraf Ibrahim, PhD

LOS ANGELES — The Lundquist Institute today announced that one of its spinoff start-up companies, Vitalex Biosciences, founded by researcher Dr. Ashraf Ibrahim, is producing an antibody that stems the spread of mucormycosis, a deadly fungal infection with an overall mortality rate of 50% and higher. Mucormycosis is an emerging infection caused by exposure to mucor, a mold commonly found in soil, plants, manure, and decaying fruits and vegetables.

Tuesday, April 27, 2021

COVID Research Supports The Institute’s Core Mission to Save Lives and Empower Healthcare Equity

LOS ANGELES, CA — April 27, 2021 — Investigators at The Lundquist Institute at Harbor-UCLA Medical Center, a leading clinical research center on life-saving vaccines and treatments, have been among the first and foremost to respond against COVID-19. Since March 2020, The Lundquist Institute has led or participated in eight COVID-19 clinical studies and the results of this research have changed the world. This timely and vigorous response was due to the number of early cases and extreme COVID-19 infection surges in south-central Los Angeles.

Saturday, April 17, 2021

Matthew Budoff, MD, Will Present the Analyses at the European Society of Cardiology (ESC) Preventive Cardiology 2021

Investigator(s): Matthew Budoff, MD

LOS ANGELES (April 17, 2021) — Today, The Lundquist Institute announced that Matthew Budoff, MD, Director of Cardiovascular CT at the Institute and Professor of Medicine at the David Geffen School of Medicine at UCLA, will present further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial as Late- Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology.

Tuesday, April 13, 2021

For Critically Ill Patients with Advanced Medical Illnesses and Poor Prognoses, Overuse of Invasive ICU Treatment May Prolong Suffering

Investigator(s): Dong Chang, MD

LOS ANGELES (April 13, 2021) — The Lundquist Institute (TLI) Investigator Dong W. Chang, MD, and his colleagues’ study on critically ill patients and ICU treatments was published in JAMA Internal Medicine. The study – “Evaluation of Time-Limited Trials Among Critically Ill Patients with Advanced Medical Illnesses and Reduction of Nonbeneficial ICU Treatments” – found that training physicians to communicate with family members of critically ill patients using a structured approach, which promotes shared decision-making, improved the quality of family meetings.

Monday, March 8, 2021

Bill & Melinda Gates Medical Research Institute To Develop Formulation

-Agreement advances evolution of synthetic lung surfactants to treat respiratory distress Syndrome in premature infants in Low- and Middle-Income Countries-

Investigator(s): Frans Walther, MD, PhD, FAAP

LOS ANGELES — The Lundquist Institute (TLI) and The Bill & Melinda Gates Medical Research Institute (Gates MRI) executed a license agreement for TLI intellectual property covering a synthetic lung surfactant formulation to be developed for respiratory distress syndrome (RDS) for premature infants in Low- and Middle-Income countries (LMIC). TLI already maintains patents on this invention in the United States, Canada and Europe.
 

Wednesday, March 3, 2021

The Lundquist Institute researchers discovered a natural compound that exhibits almost ideal male contraceptive effects in pre-clinical studies

Investigator(s): Wei Yan, MD, PhD

LOS ANGELES — In a new paper published by Nature Communications, The Lundquist Institute (TLI) Investigator Wei Yan, MD, PhD, and his research colleagues spell out an innovative strategy that has led to the discovery of a natural compound as a safe, effective and reversible male contraceptive agent in pre-clinical animal models. Despite tremendous efforts over the past decades, the progress in developing non-hormonal male contraceptives has been very limited.  

Wednesday, February 10, 2021

The grant will fund clinical trials to study the efficacy of psilocybin in treating the emotional suffering associated with terminal medical illness

Investigator(s): Charles Grob, MD

LOS ANGELES — The Lundquist Institute has received a $1.75 million grant from the Steven & Alexandra Cohen Foundation to fund a multi-site clinical trial to evaluate the efficacy and safety of the compound psilocybin in individuals with severe psychological distress associated with a terminal medical illness. The grant will also support education and outreach programs related to the use of psilocybin within the field of palliative care.

Wednesday, February 3, 2021

Amgen Golden Ticket Winners to Receive Lab Space, Mentoring and Other Benefits

THOUSAND OAKS, Calif. – Amgen (NASDAQ:AMGN) today announced a three-year, Golden Ticket sponsorship of the BioLabs LA at The Lundquist Institute (TLI) life sciences co-working space to accelerate the development of new therapies, medical devices, and diagnostics to advance and improve human health. The BioLabs at TLI shared laboratory space was created to help high-potential life science and biotech startups overcome key obstacles for many early stage organizations, including: access to laboratory infrastructure, programming, and business development mentorship.